Olanzapine

Limits on what this shows

• Key negative/null findings: None located specific to olanzapine and mitochondrial structure/biogenesis.
• At-risk subgroups: Not established in humans; both supporting sources are animal or isolated-tissue models.
• Counter-evidence on record: A related but distinct PubMed hit, Sun et al. 2022 (Biol Psychiatry, PMID 35662508), "miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia," describes mitochondrial dysfunction as a cause of poor olanzapine response, not as a consequence of olanzapine exposure, the reverse of the direction graded here. Per Hard Rule 4 this is excluded from supporting evidence and recorded here only as a direction-check note.

Regulatory status

Not a labeled effect; the FDA label does not address mitochondrial function.

Population evidence

Chen et al. 2023 (Aging Cell, PMID 37828862), "Impaired mitophagosome-lysosome fusion mediates olanzapine-induced aging," confirmed by title, journal, and PMID from the PubMed search listing; full abstract not independently reopened this session due to sustained rate-limiting, so the specific cell/tissue model and quantitative findings are not confirmed beyond the title's own claim. Eftekhari et al. 2016 (Xenobiotica, PMID 26364812), described under Oxidative stress, is a Tier B animal-tissue (freshly isolated rat hepatocyte) study explicitly finding oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity, an olanzapine-specific mitochondrial finding independent of the Chen et al. source.

Mechanism

Step 2 category E (mitochondrial interference); named as impaired mitophagosome-lysosome fusion in the Chen et al. title and as mitochondrial/lysosomal cross-talk during cytotoxicity in Eftekhari et al., though full mechanistic detail for the former could not be confirmed this session.

Framing caution

Two independent Tier B sources, but animal/cell-model only, and one (Chen et al. 2023) is confirmed at title level only this session, not full text. Should not be read as evidence of clinically meaningful mitochondrial toxicity in patients at therapeutic doses.

Limits on what this shows

• Key negative/null findings: Kramar et al. 2024 is a direct, drug-specific null finding for olanzapine (in contrast to aripiprazole, which did show an effect in the same model) and is recorded as such rather than omitted. Todorović 2016 and Stanisavljević 2017 are reverse-direction findings specific to a chronic social-isolation-stress comorbidity model, not a general claim that olanzapine lowers oxidative stress at baseline.
• At-risk subgroups: Not established in humans beyond the Wu et al. 2025 correlational cohort; the animal literature spans liver, testis, and hypothalamic-neuron tissue without a unified at-risk population identified.
• Counter-evidence on record: Directly disclosed above (Kramar 2024 null; Todorović/Stanisavljević reverse-direction); this is one of the more internally conflicted entries in this dossier and is reported as such rather than resolved artificially in one direction.

Regulatory status

Not addressed in the FDA label as an oxidative-stress effect.

Population evidence

Increased-stress direction: Bashandy et al. 2025 (BMC Pharmacol Toxicol, PMID 40229885) found olanzapine induced hepatic oxidative stress, inflammation, and insulin resistance in rats, all attenuated by co-administered zinc sulfate in a dose-dependent manner. Ebaid et al. 2025 (Biol Trace Elem Res 203:3764-3778, DOI 10.1007/s12011-024-04442-8, full text read via publisher page), 24 male rats in four groups of 6, olanzapine 10 mg/kg/day orally for 6 weeks, found olanzapine alone increased testicular oxidative stress and decreased antioxidant defenses, again attenuated by zinc sulfate co-administration; exact statistical values for the oxidative-stress markers were not retrievable from the summarized text this session. Boz et al. 2020 (Sci Rep, PMID 33154380) found N-acetylcysteine prevented olanzapine-induced oxidative stress in mHypoA-59 hypothalamic neurons (cell model). Eftekhari et al. 2016 (Xenobiotica, PMID 26364812) found oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes, a direct-toxicity, high-concentration in vitro model. A human, Tier A, drug-specific correlational source exists: Wu et al. 2025 (J Psychopharmacol, DOI 10.1177/02698811241311459), 50 olanzapine-treated schizophrenia patients, found paraoxonase-1 (PON-1) activity, an HDL-associated antioxidant enzyme, correlated with normalized olanzapine dosing and drug-level indicators, proposed as a cardiometabolic-risk monitoring tool; this is a within-treatment correlation with drug exposure, not a clearly stated before/after or versus-untreated deficit, so it does not by itself establish a bounded olanzapine-caused PON-1 deficit. Reverse/null direction: Todorović et al. 2016 (Eur J Pharm Sci, PMID 26474692) and Stanisavljević et al. 2017 (Can J Physiol Pharmacol, PMID 28177683) both found olanzapine reduced/alleviated hepatic oxidative stress and inflammation specifically in a chronic social-isolation-stress rat model. Wei et al. 2003 (J Neurosci Res, PMID 12868070) found olanzapine protected PC12 cells from hydrogen-peroxide-induced oxidative stress. Kramar et al. 2024 (Int J Mol Sci, PMID 39456900) found aripiprazole, but explicitly not olanzapine, altered the response to oxidative stress in Fao hepatoma cells, a direct olanzapine-specific null result in that model.

Mechanism

Step 2 category D (cofactor antagonism / direct enzyme effects on antioxidant systems), not resolved to a single named biochemical pathway; the literature is genuinely split between direct-toxicity/high-dose models (oxidative stress increased) and chronic-stress-comorbidity models (oxidative stress reduced), suggesting the effect may depend heavily on tissue, dose, and the presence of a superimposed stressor rather than representing one consistent baseline effect.

Framing caution

Graded yellow, not orange, because the one Tier A human source (Wu et al. 2025) is correlational with drug exposure rather than a clearly bounded deficit versus a comparator, and because the animal/cell literature is directionally mixed rather than consistent. Two of the increased-stress animal sources (Bashandy 2025 and Ebaid 2025) share overlapping senior authorship (the Bashandy research group) though they used different tissues (liver versus testis) and are not the same dataset; this partial-independence caveat is noted rather than treated as a formal source overlap.

Limits on what this shows

• Key negative/null findings: None located specific to olanzapine and iron status.
• At-risk subgroups: Not established in humans.
• Counter-evidence on record: None found directly contradicting this specific tissue-level finding; no human serum iron, ferritin, or transferrin saturation study in olanzapine-treated patients was located this session.

Regulatory status

Not addressed in the FDA label; no anemia, ferritin, or iron-status language was found in the label sections reviewed.

Population evidence

Ebaid et al. 2025 (Biol Trace Elem Res 203:3764-3778, DOI 10.1007/s12011-024-04442-8), the same study described under Oxidative stress and ATP production: in homogenized testicular tissue, olanzapine alone (10 mg/kg/day, 6 weeks, n=6) decreased iron concentration compared with control, restored toward normal by zinc sulfate co-administration. Dedicated PubMed searches for "olanzapine iron deficiency" and "olanzapine ferritin" returned no other drug-specific hits; the handful of results found (restless-legs and extrapyramidal-symptom case reports) concerned other antipsychotics or the reverse relationship (baseline iron status affecting drug-induced movement side effects), not olanzapine lowering iron, and are excluded as out of direction or out of cohort.

Mechanism

Not established; the source does not report a transporter, absorption, or hepcidin-mediated mechanism, only the measured tissue concentration change.

Framing caution

Single small animal study (n=6/group), testicular tissue only, not systemic serum iron or ferritin, and exact statistics not confirmed this session. Should not be read as evidence that olanzapine causes iron-deficiency anemia in patients; see the Oxygen delivery/utilization entry, which found no such human signal.

Limits on what this shows

• Why no grade: Both conditions for ungraded were met: no Tier B or Tier C evidence supports even a yellow grade, and no circulating consumer claim was found to rebut as white.

Channels tried

This repair pass re-ran "olanzapine copper" on PubMed (returned the same 10 results as the prior pass, confirmed rather than merely repeated), then broadened to a class-level query, "antipsychotic serum copper schizophrenia" (10 of at least 2 pages of results reviewed by title). Drugs.com food-interactions page for olanzapine was already checked directly in the prior pass for any nutrient-depletion mention (none found, applying to all nutrients, not just copper). This pass additionally attempted to open individual PubMed abstract pages, the Crossref works API, the Europe PMC REST API, the Semantic Scholar Graph API, and the OpenAlex works API for the most promising class-level hits.

What happened

The drug-specific "olanzapine copper" results were unchanged from the prior pass: an HPLC analytical-artifact paper, two Wilson's disease case reports (a genetic copper-overload disorder, olanzapine used incidentally to manage symptoms), a cuprizone-demyelination-model study using cuprizone as an experimental neurotoxin rather than testing olanzapine's effect on physiological copper, and unrelated oxidative-stress papers. The broader class-level query surfaced three titles worth naming: Saghazadeh et al. 2020, a systematic review and meta-analysis of trace elements across 39 schizophrenia studies (PMID 31800085); Chen et al. 2018, "Association of Serum Trace Elements with Schizophrenia and Effects of Antipsychotic Treatment" (PMID 28470477); and Herrán et al. 2000, "Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics" (PMID 10788677), whose title states a direction, an increase, not a depletion, associated with antipsychotic treatment generally. None of the three could be opened this session to confirm whether olanzapine specifically was in the studied cohort or, for the two whose titles do not state a direction, which way any effect ran: PubMed's individual abstract pages returned bot-verification or empty-shell content, and the Crossref, Europe PMC, Semantic Scholar, and OpenAlex API calls all returned HTTP 403 at the outbound proxy gateway, confirmed as a policy-level connection rejection (not a per-request rate limit) by the proxy's own status log for api.crossref.org, www.ebi.ac.uk, and api.openalex.org across this session. The Ebaid et al. 2025 testicular-tissue study (used for Iron, Zinc, and ATP production) remains unconfirmed on whether it reported copper as a measured outcome, for the same reason.

Assessment

Still a genuine literature gap for a depletion claim specifically: no source found or reachable this session states that olanzapine, or any named atypical antipsychotic, lowers copper status, and the one source whose direction is known (Herrán et al. 2000) points the opposite way. This is a stronger basis for leaving copper ungraded than the prior pass had, not a tooling failure being mistaken for a negative finding, though whether Saghazadeh 2020 or Chen 2018 stratify results by drug (which could in principle support a class-extrapolated yellow grade for some other nutrient in a future revision) remains genuinely unconfirmed and access-blocked.

Limits on what this shows

• Key negative/null findings: Qian et al. 2023 explicitly disclose their own design limitation (correlational, no causal experiment in that particular study) rather than overstating it; this is recorded as a disclosed boundary, not a null finding.
• At-risk subgroups: Not established in humans; Abbas et al. 2022's title indicates sex-differential effects in mice, unconfirmed in detail this session.
• Counter-evidence on record: Cussotto et al. 2021 (EBioMedicine, PMID 33819741), "The gut microbiome influences the bioavailability of olanzapine in rats," found the opposite-direction relationship, the microbiome affecting olanzapine's pharmacokinetics rather than olanzapine damaging the microbiome, confirmed by title and journal from the PubMed search listing. Per Hard Rule 4, this is recorded as a distinct, reverse-direction pharmacokinetic interaction, not used as supporting evidence for this entry, and is a reason a prescriber should not assume a stable microbiome state given how variable olanzapine exposure itself may be as a result.

Regulatory status

Not addressed in the FDA label.

Population evidence

Qian et al. 2023 (Microbiol Spectr, PMID 37260381, DOI 10.1128/spectrum.00058-23, open access, full text read): two female Sprague-Dawley rat studies, olanzapine specifically administered. Study 1 (n=11/group) dosed olanzapine at 2, 4, or 8 mg/kg/day or vehicle for 28 days. Study 2 (n=16/group) dosed olanzapine at 4 mg/kg/day or vehicle for 12 days with fecal sampling at baseline, day 4, 8, and 12. Genera positively correlated with weight gain included Enterorhabdus (r=0.38), Parasutterella (r=0.43), and Prevotellaceae UCG-001 (r=0.52); over time, Enterorhabdus, Bacteroides, Butyricimonas, and Phascolarctobacterium increased while Prevotella, Allobaculum, and "Candidatus Arthromitus" decreased; at the phylum level, Firmicutes rose from 45% to 53% and Bacteroidota fell from 50% to 42%. The authors state explicitly that this is correlational: no fecal transplant or germ-free-mouse experiment was performed, and "the functional role and mode of action of the identified gut microbiota are still not clear." Kao, Lennox, and Burnet 2018 (Transl Psychiatry, and a related paper in Eur Neuropsychopharmacol) used a prebiotic (galacto-oligosaccharide) intervention in rats and found it attenuated olanzapine-induced weight gain while altering gut microbiota and central/peripheral biomarkers, an intervention design that supports a causal, not merely correlational, role for the microbiota. Wu et al. 2025 (Am J Physiol Gastrointest Liver Physiol, PMID 39679941) transplanted gut microbiota from human patients who were insusceptible to olanzapine-induced fatty liver disease into rats and found it relieved hepatic steatosis, a fecal-microbiota-transplant design that is the strongest causality evidence in this set. Wang et al. 2025 (Microb Biotechnol, PMID 41376147) found Akkermansia muciniphila alleviated olanzapine-induced hepatic steatosis via a gut microbiota-IGFBP2/APOA1-liver axis, consistent with the reduced-Akkermansia pattern reported for antipsychotics generally. Zhu et al. 2022 (Front Pharmacol, PMID 35991866) and Abbas et al. 2022 (Nutrients, PMID 35057526, mice) add further olanzapine-specific animal evidence linking gut microbiota to lipid disturbance and diet-by-sex interactions; these were confirmed by title, journal, and PMID from the PubMed search listing but not individually reopened for full abstract text this session. A genuine human cohort study, Pełka-Wysiecka et al. 2019 (J Clin Med, PMID 31623359), titled "Analysis of Gut Microbiota and Their Metabolic Potential in Patients with Schizophrenia Treated with Olanzapine," was confirmed to exist via the PubMed search listing (title, journal, year, PMID) but its abstract could not be retrieved this session: the individual PubMed page returned blank content, a Crossref bibliographic search for the exact title failed to match it, and a guessed DOI could not be confirmed before sustained rate-limiting closed off further attempts.

Mechanism

Step 2 category G (microbiome disruption), supported by a phylum-level Firmicutes/Bacteroidota shift and specific weight-gain-correlated genera in Qian et al. 2023, and by causal rescue (prebiotic) and causal transfer (fecal transplant) experiments in the other animal studies, though no single study in this set both establishes drug-specific causality and quantifies it in a human cohort.

Framing caution

Graded yellow, not orange, because no Tier A human study's content could be verified this session, only its existence. This is nonetheless an unusually deep Tier B animal literature for this review, spanning correlational dosing studies, a prebiotic-rescue intervention, and a fecal-transplant causality experiment, a stronger and more varied evidence base than a single mechanistic study would provide, even though it remains animal-only by what this session could confirm. Tooling disclosure: PubMed's individual abstract pages returned blank/empty content for multiple PMIDs in this category across the session (not merely a single blocked attempt), and Europe PMC, OpenAlex, and Semantic Scholar were also rate-limited or connection-refused for extended stretches; a future pass should specifically retry Pełka-Wysiecka et al. 2019 (PMID 31623359) for its taxa-level results.

Limits on what this shows

• Key negative/null findings: None located specific to olanzapine and ATP production.
• At-risk subgroups: Not established in humans; this is a single animal study in testicular tissue specifically, not a systemic or whole-body energy-metabolism measure.
• Counter-evidence on record: None found; no human or systemic-tissue ATP-production study in olanzapine-treated subjects was located this session.

Regulatory status

Not a labeled effect.

Population evidence

Ebaid et al. 2025 (Biol Trace Elem Res 203:3764-3778, DOI 10.1007/s12011-024-04442-8), the same study described under Oxidative stress and Iron: 24 male rats, four groups of 6, olanzapine 10 mg/kg/day orally for 6 weeks, versus control, versus olanzapine plus zinc sulfate at 50 or 100 mg/kg. Homogenized testicular tissue showed decreased concentrations of the "energy storage indicator (ATP)" in the olanzapine-alone group compared with control, restored toward normal in a dose-dependent manner by zinc sulfate co-administration. Exact statistical values (means, percent change, or p-values) for the ATP finding were not retrievable from the summarized publisher text accessed this session.

Mechanism

Not established beyond the observed association with tissue oxidative stress and trace-mineral depletion in the same study; no electron-transport-chain or ATP-synthase-specific assay is described in the material retrieved.

Framing caution

Single animal study, small sample (n=6/group), one non-reproductive-outcome-relevant tissue (testis), and exact statistics not confirmed this session. Reported as a distinct entry from Mitochondrial burden per the project's rule against merging them, but it rests on a source shared with Iron below; see the overlap map.

Limits on what this shows

• Why no grade: Both conditions for ungraded were met: no Tier B or Tier C evidence supports even a yellow grade, and no circulating consumer claim was found to rebut as white.

Channels tried

The prior pass's "olanzapine hemoglobin" and "olanzapine anemia" PubMed queries; the DailyMed SPL hematologic-effects section (5.9), reviewed directly for any red-cell, hemoglobin, or hematocrit language. This repair pass re-ran "olanzapine hemoglobin" fresh (a full 10 results returned) and attempted "olanzapine anemia" and "olanzapine hematocrit OR olanzapine erythropoietin" as follow-ups, plus checked whether the companion risperidone dossier's pediatric Calarge/Bahr cohort studies (cited there for Iron and Gut microbiome risk) report hemoglobin or hematocrit for an olanzapine comparator arm.

What happened

The fresh "olanzapine hemoglobin" search returned 10 results, none an olanzapine-specific hemoglobin, hematocrit, or anemia finding: a semaglutide-in-clozapine/olanzapine-patients metabolic study (Sass et al. 2023, PMID 36720576) that does not appear, by title, to be hemoglobin-focused; diabetic-ketoacidosis case reports (a glucose, not oxygen-carrying, finding); a mechanistic paper on antipsychotics clozapine, ziprasidone, and sertindole binding human hemoglobin (Platanić Arizanović et al. 2023, PMID 37240267, olanzapine not among the three named drugs, excluded as out of cohort); and a clozapine-induced-anemia case report (a different drug, excluded). Both follow-up queries, "olanzapine anemia" and the hematocrit/erythropoietin query, were blocked by the outbound proxy before returning results. The Calarge and Bahr papers cited in the risperidone dossier could not be opened this session for the same reason, so whether they report hemoglobin or hematocrit for any comparator drug, including olanzapine, remains unconfirmed rather than ruled out. The DailyMed label's hematologic-effects language (Section 5.9) still addresses only leukopenia, neutropenia, and agranulocytosis, all white-cell/immune findings, with no mention of hemoglobin, hematocrit, or red-cell mass; a fresh DailyMed re-check this session was itself blocked at the proxy.

Assessment

Likely still a genuine literature gap for olanzapine specifically, now supported by a completed rather than partial "olanzapine hemoglobin" search, but the follow-up queries and the Calarge/Bahr cross-check remain unresolved rather than closed. A future pass should specifically retry "olanzapine anemia," "olanzapine hematocrit," a fresh DailyMed fetch, and opening the Calarge 2016 ferritin paper (PMID 26894929) and Bahr 2015 papers directly for a hemoglobin or hematocrit figure before this category is treated as fully settled.